6-((tert-butyldiphenylsilyl)oxy)-3-iodo-1H-indazole | 1204772-91-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 6-((tert-butyldiphenylsilyl)oxy)-3-iodo-1H-indazole
• 英文别名: 6-(Tert-butyldiphenylsilyloxy)-3-iodoindazole；6-(t-butyldiphenylsiloxy)-3-iodo-1H-indazole；tert-butyl-[(3-iodo-2H-indazol-6-yl)oxy]-diphenylsilane
• CAS: 1204772-91-7
• 化学式: C₂₃H₂₃IN₂OSi
• 分子量: 498.438
• InChiKey: CRQBLTRHAJIXMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.11
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-((tert-butyldiphenylsilyl)oxy)-3-iodo-1H-indazole 在 4-二甲氨基吡啶 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 偶氮二甲酰胺 、 水 、 三乙胺 、 三苯基膦 、 三(邻甲基苯基)磷 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β₃-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

  摘要：

  Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human A-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant beta(3)-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the alpha(1A)-AR (EC50 = 219 nM, selectivity: alpha(1A)/beta(3) = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for beta(3)-AR agonistic activity versus au-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent beta(3)-AR agonistic activity (EC50 = 13 nM) and high selectivity (alpha(1A)/beta(3) = >769-fold). Compound 11 was also inactive toward beta(1) and beta(2)-ARs and showed dose dependent beta(3)-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.

  DOI：

  10.1021/acs.jmedchem.5b00638
• 作为产物：
  描述：

  6-((tert-butyldiphenylsilyl)oxy)-1H-indazole 在 potassium tert-butylate 、 碘 作用下， 以 四氢呋喃 为溶剂， 生成 6-((tert-butyldiphenylsilyl)oxy)-3-iodo-1H-indazole
  参考文献：
  名称：

  INDAZOLE COMPOUNDS

  摘要：

  提供的是以下公式（A-1）和公式（1）所代表的化合物，或其盐。公式（A-1）和公式（1）的化合物或其盐具有133肾上腺素受体激动剂活性，因此可作为治疗和预防糖尿病、肥胖、高脂血症、抑郁症、胆石症或胆道高动力性疾病、消化系统过度活动引起的疾病、间质性膀胱炎、膀胱过度活动或尿失禁的药物，或作为治疗和预防伴随眼泪减少的疾病的药物。

  公开号：

  US20100160256A1

文献信息

• BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS
  申请人：Atobe Masakazu

  公开号：US20100029733A1

  公开（公告）日：2010-02-04

  A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, as an active ingredient of a medicine for the prevention and/or treatment of overactive bladder. The compound is also useful as an active ingredient of a medicine for the prevention and/or treatment of symptoms such as frequency urinary, urinary urgency, or urinary incontinence.

  提供一种由以下式（1）表示的含氮双环杂环化合物。当该化合物或其盐被用于人类或动物时，该化合物对EP1受体具有强烈的拮抗作用，并且可用作预防和/或治疗膀胱过度活跃的药物的活性成分。该化合物还可用作预防和/或治疗频繁排尿、尿急或尿失禁等症状的药物的活性成分。